Company Overview

Jaguar Health, Inc. is a U.S.-based commercial-stage pharmaceuticals and plant-based therapeutics company focused on developing and commercializing prescription medicines derived from sustainably harvested rainforest botanicals. The company primarily operates in the gastrointestinal health and supportive care markets, with an emphasis on treatments for chronic and debilitating diarrhea conditions in both human and animal health applications. Jaguar Health’s principal commercial product is crofelemer, marketed under the brand name Mytesi, which is approved in the United States for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also pursues additional indications for crofelemer involving rare diseases, cancer therapy-related diarrhea, and inflammatory gastrointestinal disorders.

The company traces its origins to Jaguar Animal Health, founded in 2013 by entrepreneur and executive Lisa A. Conte, before evolving into Jaguar Health through public market transactions and strategic restructuring. Jaguar expanded beyond veterinary applications into human pharmaceuticals through the acquisition and integration of Napo Pharmaceuticals, Inc., which became a core operating subsidiary and intellectual property holder for crofelemer-related assets. Jaguar Health positions itself through a differentiated strategy centered on botanical drug development, orphan and supportive care indications, and proprietary plant-derived formulations supported by regulatory pathways established under U.S. FDA botanical drug guidance.

Business Operations

Jaguar Health generates revenue primarily through sales of Mytesi and related pharmaceutical commercialization activities conducted through Napo Pharmaceuticals, Inc. The company’s operations are organized around human health therapeutics, while historically maintaining interests in animal health gastrointestinal products. Crofelemer remains the company’s principal asset and revenue driver, supported by intellectual property rights, supply agreements, and regulatory exclusivity in approved indications. Jaguar Health’s development activities include clinical programs evaluating crofelemer for diarrhea associated with cancer therapies, rare diseases, and gastrointestinal complications affecting underserved patient populations.

The company operates principally in the United States, while also pursuing international licensing, clinical collaborations, and market expansion opportunities in regions including Europe, Latin America, and parts of Africa. Jaguar Health controls proprietary botanical extraction and formulation technologies linked to rainforest-derived medicinal plants. Strategic collaborations have included relationships with academic institutions, clinical research organizations, and specialty pharmaceutical commercialization partners. Public disclosures in SEC filings and investor materials identify Napo Pharmaceuticals, Inc. as a major subsidiary central to regulatory, commercialization, and development operations.

Strategic Position & Investments

Jaguar Health’s strategic direction focuses on expanding crofelemer into additional therapeutic indications beyond HIV-related diarrhea, particularly in oncology supportive care and rare gastrointestinal diseases. The company has invested in clinical studies evaluating crofelemer for cancer therapy-related diarrhea, including diarrhea associated with targeted therapies and immunotherapies. Management has emphasized orphan disease pathways and unmet medical needs as core growth areas due to potentially accelerated regulatory pathways and specialized market positioning.

The company’s major strategic asset remains Napo Pharmaceuticals, Inc., which holds key intellectual property and commercialization rights associated with crofelemer. Jaguar Health has also explored partnerships and licensing arrangements intended to broaden global commercialization opportunities and diversify clinical applications. The company’s broader investment strategy centers on plant-based pharmaceutical development, sustainable sourcing practices, and leveraging FDA-recognized botanical drug frameworks. Publicly available information indicates continued investment in clinical development and regulatory expansion rather than large-scale acquisition activity compared with larger pharmaceutical peers.

Geographic Footprint

Jaguar Health is headquartered in San Francisco, California, and conducts most of its commercial and corporate activities within the United States. The company’s commercial footprint is concentrated in the U.S. pharmaceutical market due to the FDA approval and commercialization of Mytesi, though its clinical and strategic initiatives extend internationally through partnerships and research collaborations.

The company’s sourcing and development model also reflects operational connections to rainforest regions in South America, where botanical raw materials associated with crofelemer are sustainably harvested. Jaguar Health has pursued market development and licensing discussions in regions including Europe, Latin America, and selected emerging healthcare markets. While its global operating scale remains relatively limited compared with multinational pharmaceutical companies, the company maintains international influence through intellectual property licensing, clinical outreach, and botanical supply chain relationships.

Leadership & Governance

Jaguar Health was founded by Lisa A. Conte, who has played a central role in shaping the company’s strategic direction around botanical pharmaceuticals, gastrointestinal therapeutics, and sustainable biopharmaceutical development. The company’s leadership philosophy has consistently emphasized addressing unmet medical needs through plant-derived medicines supported by regulatory science and targeted commercialization strategies. Corporate governance and operational oversight are conducted through executive leadership and the board structure disclosed in public filings including SEC filings and annual reports.

Key executives include:

• Lisa A. Conte – Founder, President, and Chief Executive Officer
• Carolyn E. Mitchell – Chief Financial Officer
• Pravin Chaturvedi, Ph.D. – Chair of the Board of Directors
• Thomas J. Graham – General Counsel and Corporate Secretary

Information regarding executive roles and organizational structure has been consistently identified across company regulatory disclosures, investor communications, and public corporate filings.